Literature DB >> 21576832

The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.

Yasuji Arase1, Fumitaka Suzuki, Mariko Kobayashi, Yoshiyuki Suzuki, Yusuke Kawamura, Naoki Matsumoto, Norio Akuta, Masahiro Kobayashi, Hitomi Sezaki, Satoshi Saito, Tetsuya Hosaka, Kenji Ikeda, Hiromitsu Kumada, Yuki Ohmoto, Kazuhisa Amakawa, Hiroshi Tsuji, Shiun Dong Hsieh, Kazuhisa Kato, Maho Tanabe, Kyoko Ogawa, Shigeko Hara, Tetsuro Kobayashi.   

Abstract

Objective Chronic kidney disease (CKD) is present in patients with nonalcoholic fatty liver disease (NAFLD). The aim of this retrospective study was to assess the cumulative development incidence and predictive factors for new onset of CKD in Japanese patients with NAFLD. Methods A total of 5,561 NAFLD patients without CKD were enrolled. CKD was defined as either an estimated glomerular filtration rate of <60 mL/min/1.73 m(2) or dipstick proteinuria (≥+1). A blood sample and a urine sample were taken for routine analyses during follow-up. The mean observation period was 5.5 years. The primary goal is the new development of CKD. Independent factors associated with new development of CKD were analyzed by using the Kaplan-Meyer method and the Cox proportional hazards model. Results Of 5.561 NAFLD patients, 263 patients developed CKD. The cumulative development rate of CKD was 3.1% at the 5th year and 12.2% at the 10th year. Multivariate Cox proportional hazards analysis showed that CKD development in patients with NAFLD occurred when patient had low level of GFR of 60-75 mL/min/1.73 m(2) [hazard ratio:2.75; 95% confidence interval (CI)=1.93-3.94; p<0.001], age of ≥50 years (hazard ratio: 2.67; 95% CI=2.06-3.46; p<0.001), diabetes (hazard ratio: 1.92; 95% CI=1.45-2.54; p<0.001), hypertension (hazard ratio: 1.69; 95% CI=1.25-2.29; p<0.001), and elevated serum gamma-glutamyltransferase of ≥109 IU/L (hazard ratio: 1.35; 95% CI=1.02-1.78; p=0.038). Conclusion Our retrospective study indicates that the annual incidence of CKD in Japanese patients with NAFLD is about 1.2%. Five factors of low eGFR level, aging, type 2 diabetes, hypertension, and elevated gamma-glutamyltransferase, increases the risk of the development of CKD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576832     DOI: 10.2169/internalmedicine.50.5043

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  12 in total

Review 1.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

2.  Reply to "Obstructive sleep apnea patients without hypertension or diabetes and subsequent incidence of chronic kidney disease" by Kawada (letter to the editor).

Authors:  Yu-Sheng Lin; Pi-Hua Liu; Ning-Hung Chen
Journal:  Sleep Breath       Date:  2017-11-04       Impact factor: 2.816

3.  Liver steatosis and the risk of albuminuria: the multi-ethnic study of atherosclerosis.

Authors:  Ravi V Shah; Matthew A Allison; Joao A C Lima; Siddique A Abbasi; Morgana Mongraw-Chaffin; Michael Jerosch-Herold; Jingzhong Ding; Matthew J Budoff; Venkatesh L Murthy
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

4.  Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.

Authors:  Chan-Young Jung; Geun Woo Ryu; Hyung Woo Kim; Sang Hoon Ahn; Seung Up Kim; Beom Seok Kim
Journal:  Diabetologia       Date:  2021-12-21       Impact factor: 10.122

Review 5.  Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect.

Authors:  Rajiv Heda; Masahiko Yazawa; Michelle Shi; Madhu Bhaskaran; Fuad Zain Aloor; Paul J Thuluvath; Sanjaya K Satapathy
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

6.  Implication of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, and Subclinical Inflammation on Mild Renal Insufficiency.

Authors:  Ga Eun Nam; Soon Young Hwang; Hye Soo Chung; Ju Hee Choi; Hyun Jung Lee; Nam Hoon Kim; Hye Jin Yoo; Ji-A Seo; Sin Gon Kim; Nan Hee Kim; Sei Hyun Baik; Kyung Mook Choi
Journal:  Int J Endocrinol       Date:  2018-04-02       Impact factor: 3.257

7.  Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Authors:  Yoshitaka Arase; Koichi Shiraishi; Kazuya Anzai; Hirohiko Sato; Erika Teramura; Kota Tsuruya; Shunji Hirose; Ryuzo Deguchi; Masao Toyoda; Tetsuya Mine; Tatehiro Kagawa
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

Review 8.  The Wide and Complex Field of NAFLD Biomarker Research: Trends.

Authors:  Erika Wichro; Tanja Macheiner; Jasmin Schmid; Barbara Kavsek; Karine Sargsyan
Journal:  ISRN Hepatol       Date:  2014-04-28

9.  Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west?

Authors:  Min Zhang; Su Lin; Ming-Fang Wang; Jiao-Feng Huang; Shi-Ying Liu; Su-Mei Wu; Hao-Yang Zhang; Zi-Mu Wu; Wen-Yue Liu; Dong-Chu Zhang; Chuan-Ming Hao; Yue-Yong Zhu; Ming-Hua Zheng; Xiao-Zhong Wang
Journal:  BMC Gastroenterol       Date:  2020-05-06       Impact factor: 3.067

10.  Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan.

Authors:  Kota Yano; Yuya Seko; Aya Takahashi; Shinya Okishio; Seita Kataoka; Masashi Takemura; Keiichiroh Okuda; Naoki Mizuno; Hiroyoshi Taketani; Atsushi Umemura; Taichiro Nishikawa; Kanji Yamaguchi; Michihisa Moriguchi; Takeshi Okanoue; Yoshito Itoh
Journal:  Diagnostics (Basel)       Date:  2020-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.